Please login to the form below

Halozyme Therapeutics

This page shows the latest Halozyme Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Halozyme to resume pancreatic cancer study

There was relief for Halozyme Therapeutics after it was told it can resume a clinical study investigating a potential treatment for pancreatic cancer. ... With the trial now back underway, Halozyme said it intends to recruit another 100 patients to add

Latest news

Halozyme halts pancreatic cancer trial

Halozyme halts pancreatic cancer trial. The biopharma company is investigating PEGPH20’ s links to blood clot. ... Halozyme Therapeutics has paused a phase II trial of its investigational pancreatic cancer drug in order to assess the candidate's safety.
Baxter re-files HyQvia for immunodeficiency in US

HyQvia - which uses delivery technology developed by Halozyme Therapeutics - is a combination of human normal immunoglobulin (IG) and recombinant human hyaluronidase which can be delivered by subcutaneous injection every three to ... Meanwhile, for
Roche wins EU approval for injectable Herceptin

Roche developed subcutaneous Herceptin using recombinant human hyaluronidase technology developed by US-based biopharma company Halozyme Therapeutics.
Roche's Perjeta backed in EU for breast cancer

Roche is also developing additional products intended to protect its Herceptin franchise, including a subcutaneous formulation of trastuzumab - partnered with Halozyme Therapeutics - that is also in the latter stages of development.
Roche's T-DM1 activity in breast cancer "outstanding"

Roche is developing additional products intended to protect its Herceptin franchise, including a subcutaneous formulation of the drug partnered with Halozyme Therapeutics which is scheduled for filing later this year.

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Pharma deals in June 2015

Acquisition - company. 1, 470. Halozyme Therapeutics/ AbbVie. ENHANZE platform technology to improve sc delivery (up to 9 targets). ... NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology
Deal Watch table for December 2014

Expansion of collaboration/ amended agreement. 675. Halozyme Therapeutics / J&J. ENHANZE rHuPH20 delivery technology for up to 5 targets. ... Licence - amended agreement. † 300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy products
Pharma deals during December 2014

Switching to drug delivery technologies, J&J/Janssen entered into a global licence with Halozyme Therapeutics to access Halozyme's ENHANZE technology, which is designed to enable subcutaneous administration of injectable ... Subcutaneous formulations of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Amgen veteran Kurt Gustafson joins Spectrum as CFO

He joins Spectrum from fellow US biotech Halozyme Therapeutics, where he served as VP and chief financial officer.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Account Manager – Healthcare Advertising: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Manager- 4 days per week or full-time: Salary TBC

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Systematic Review Lead- London: Negotiable

Sudler London - Account Director: Competitive

Graduate Scientific Editor: DOE

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Medical Writer - Creative and Scientific Projects: DOE

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Medical Writer, MedComms Agency: Salary TBC

Account Manager: Negotiable

Account Director or Senior Account Director: Salary TBC

Associate Scientific Director: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Senior Writer, Healthcare Advertising, London: Excellent package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Subscribe to our email news alerts

PMHub

Add my company

emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....